Our Pricing

Wegovy Price UK: All Doses Available & In Stock Now

Published on: June 03, 2026

Searching for transparent wegovy price uk online pharmacy information? At Cured Pharmacy, Wegovy (semaglutide) is available from £79.00 with all doses in stock, upfront pricing shown before consultation, and a UK-registered clinical team ready to assess your suitability in under 3 minutes.

Understanding Wegovy Price UK: What You Actually Pay

Wegovy pricing in the UK varies significantly between providers, but at Cured Pharmacy, you'll see the exact cost before completing your clinical assessment. Wegovy is available from £79.00, with your final price determined by the dose your UK prescriber recommends based on your individual clinical needs and treatment progression [1].

Unlike some providers who display starting prices but add consultation fees, delivery charges, or hidden costs at checkout, our pricing is transparent and includes your medication, clinical assessment by a UK-registered prescriber, and discreet delivery to your door. All Wegovy pens dispensed are genuine UK-licensed medicines sourced through regulated pharmaceutical supply chains, ensuring you receive the same quality medication available through traditional pharmacy channels [2].

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating. This medication works through three complementary mechanisms: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and helps regulate blood sugar levels [1][3].

In the landmark STEP 1 clinical trial, adults using Wegovy alongside lifestyle modifications achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The STEP 2 trial specifically examined patients with type 2 diabetes, demonstrating an average weight loss of 9.6% alongside improvements in glycaemic control [3]. These results represent some of the most significant weight loss outcomes seen with any licensed pharmacological treatment in UK clinical practice.

The Science Behind Semaglutide

Semaglutide's molecular structure has been modified to extend its half-life to approximately one week, which is why Wegovy requires only once-weekly administration [2]. This extended action is achieved through albumin binding and resistance to DPP-4 enzyme degradation, allowing steady therapeutic levels throughout the week. The medication is identical to the semaglutide used in diabetes management but is prescribed at higher doses specifically licensed for chronic weight management by the MHRA.

Wegovy Dosing Schedule: All Doses In Stock

Wegovy follows a carefully structured dose escalation schedule designed to minimise gastrointestinal side effects whilst building therapeutic efficacy. Your treatment typically begins with 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses, reaching the maintenance dose of 2.4mg by week 17 [4].

At Cured Pharmacy, we maintain stock of all Wegovy doses, which is particularly important given the supply challenges that have affected UK availability in recent months. Having consistent access to each escalation dose ensures you can progress through the titration schedule without interruption, which is clinically important for both tolerability and sustained weight loss outcomes [4]. Your UK prescriber will determine the appropriate starting dose and escalation timeline based on your individual response and any side effects experienced.

What Happens If You Miss a Dose

If you miss a Wegovy injection and it's been less than five days since your scheduled dose, administer it as soon as you remember. If more than five days have passed, skip the missed dose and resume your regular schedule with the next planned injection [4]. Never double up doses to compensate for a missed injection, as this increases the risk of gastrointestinal side effects without improving efficacy.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss treatments are now licensed in the UK, each working through different mechanisms and offering varying efficacy profiles. Wegovy represents the first-generation GLP-1 receptor agonist approved specifically for weight management, whilst newer dual-agonist medications target additional metabolic pathways.

Clinical trial data helps contextualise these differences. Whilst Wegovy demonstrated average weight loss of 14.9% in STEP 1, newer dual GIP/GLP-1 agonists have shown even greater reductions in some trials [1][5]. However, individual response varies considerably, and factors including your medical history, concurrent medications, tolerance of side effects, and personal preferences all influence which treatment your prescriber recommends. Some patients may also be suitable for oral medications or combination approaches depending on their clinical circumstances.

Who Can Use Wegovy: Eligibility Criteria

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [2]. NICE guidance supports its use within these parameters when provided alongside a reduced-calorie diet and increased physical activity.

However, several contraindications and cautions apply. Wegovy should not be used if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or if you're pregnant or breastfeeding [4]. Your UK prescriber will review your complete medical history during the online consultation, including current medications, to ensure Wegovy is safe and appropriate for you. This assessment typically takes under three minutes to complete and is conducted by GPhC-registered prescribers working under the clinical governance of our superintendent pharmacist, Tarun Kumar (GPhC 2233073).

Medical Conditions That Require Special Consideration

Certain medical conditions require careful evaluation before starting Wegovy. If you have a history of pancreatitis, severe gastroparesis, inflammatory bowel disease, or diabetic retinopathy, your prescriber will assess whether the benefits outweigh potential risks in your individual case [4]. Patients taking insulin or insulin secretagogues may require dose adjustments to reduce hypoglycaemia risk when starting Wegovy, even when it's prescribed primarily for weight management rather than diabetes.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported adverse events with Wegovy, affecting more than 10% of users in clinical trials. Nausea, diarrhoea, vomiting, constipation, and abdominal pain typically emerge during dose escalation and often diminish as your body adapts to the medication [1][4].

Practical management strategies can significantly improve tolerability. Eating smaller, more frequent meals rather than large portions, avoiding high-fat foods that slow gastric emptying further, and staying well-hydrated all help reduce gastrointestinal symptoms. If side effects are particularly troublesome, your prescriber may recommend staying at your current dose for an additional month before escalating, or in some cases, stepping back to the previous dose temporarily [4]. Most patients find these effects manageable and temporary, but it's important to report persistent or severe symptoms to your healthcare provider, as dose adjustment or treatment discontinuation may occasionally be necessary.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Wegovy 2.4 mg solution for injection in pre-filled pen. GOV.UK. [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and individual results may vary. The clinical trial data referenced represents average outcomes and does not guarantee specific results for any individual patient.